Navigation Links
SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Date:9/1/2009

AMSTERDAM, September 1 /PRNewswire/ -- SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The undisclosed company's product is an innovative live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.

"We are extremely pleased to be working with our first Japanese partner," commented SynCo's CEO, Mr. Pierre Warffemius, "this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo's entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market."

SynCo is a specialist in the development of manufacturing processes and GMP production of live biotherapeutics and provides a one-stop-shop for the production of both bulk drug substance and final lyophilized product. This project is one of a rapidly growing number SynCo is involved with in this field.

For more information, please visit http://www.syncobiopartners.com

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo 's team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.

http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
2. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
3. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
4. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
5. OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners
6. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
7. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
8. MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging
9. Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership
10. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
11. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):